Cor Vasa 2020, 62(Suppl. 1):37-40 | DOI: 10.33678/cor.2020.053

Early antithrombotic therapy and COVID-19: a better clinical course? New evidences from real-life cases

Matteo Casalea, Egidio Imbalzanob, Claudia Morabitob, Marianna Gigliotti De Faziob, Pasquale Creab, Maurizio Mezzettia, Paolo Busaccaa, Michele Correalec, Salvatore Santo Signorellid, Giuseppe Dattilob
a Operative Unit of ICCU and Cardiology, Hospital "S. Maria della Misericordia", ASUR Marche - Area Vasta 1, Urbino, Italy
b Department of Clinical and Experimental Medicine, University of Messina, Messina, Italy
c Operative Unit of ICCU and Cardiology, University Hospital, Foggia, Italy
d Department of Clinical and Experimental Medicine, University of Catania, Catania, Italy

The recent COVID-19 carries potential risk factors for VTE and worse clinical course in some patients has an association with thrombosis. While low molecular weight heparins are under investigation for appropriate dosage, other elements could be useful. We share our experience about two patients with unexpected clinical course.

Keywords: COVID-19, DOAC, Edoxaban, Low molecular weight heparin, Thromboembolism

Received: May 21, 2020; Revised: May 21, 2020; Accepted: May 22, 2020; Published: June 22, 2020  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Casale M, Imbalzano E, Morabito C, De Fazio MG, Crea P, Mezzetti M, et al.. Early antithrombotic therapy and COVID-19: a better clinical course? New evidences from real-life cases. Cor Vasa. 2020;62(Suppl. 1):37-40. doi: 10.33678/cor.2020.053.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Samama MM, Cohen AT, Darmon J-Y, et al. A comparison of enoxaparin with placebo for the prevention of venous thromboembolism in acutely ill medical patients. N Engl J Med 1999;341:793-800. Go to original source... Go to PubMed...
    2. Wang D, Hu B, Hu C, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA 2020;323:1061-1069. Go to original source... Go to PubMed...
    3. Tang N, Bai H, Chen X, et al. Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy. J Thromb Haemost 2020;18:1094-1099. Go to original source... Go to PubMed...
    4. Danzi GB, Loffi M, Galeazzi G, Gherbesi E. Acute pulmonary embolism and COVID-19 pneumonia: a random association? Eur Heart J 2020 Mar 30. pii: ehaa254. doi: 10.1093/eurheartj/ehaa254. Go to original source... Go to PubMed...
    5. Zhang P, Zhu L, Cai J, et al. Association of Inpatient Use of Angiotensin Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers with Mortality Among Patients With Hypertension Hospitalized With COVID-19. Circ Res 2020 Apr 17. doi: 10.1161/CIRCRESAHA.120.317134. Go to original source... Go to PubMed...
    6. Cui S, Chen S, Li X, et al. Prevalence of venous thromboembolism in patients with severe novel coronavirus pneumonia. J Thromb Haemost 2020 Apr 9. doi: 10.1111/jth.14830. [Epub ahead of print] Go to original source... Go to PubMed...
    7. Wang J, Hajizadeh N, Moore EE, et al. Tissue Plasminogen Activator (tPA) Treatment for COVID-19 Associated Acute
    8. Respiratory Distress Syndrome (ARDS): A Case Series. J Thromb Haemost 2020 Apr 8. doi: 10.1111/jth.14828. Go to original source... Go to PubMed...
    9. Dattilo G, Falanga G, Casale M, et al. Oral Anticoagulants: Old and New Therapy. In: Bernhardt LV (Ed.). Advances in Medicine and Biology. New York: Nova Science Publishers, Inc., 2015:13-70.
    10. Casale M, Mezzetti M, Tulino V, et al. Therapy Of Cardiac Arrhythmias In Children: An Emerging Role Of Electroanatomical Mapping Systems. Curr Vasc Pharmacol 2018;16:528-533. Go to original source... Go to PubMed...
    11. Casale M, Quattrocchi S, Bitto R, Dattilo G. Cardiac implantable devices and Takotsubo syndrome. A rare but potential eventuality. Cor Vasa 2018;60:e500-e502. Go to original source...
    12. Scarano M, Gizzi G, Mastrodicasa D, Mantini C. Cardiac implantable electronic devices and chemotherapy: A risky combination. Cor Vasa 2018;60:e469-e471. Go to original source...
    13. Testa S, Paoletti O, Giorgi-Pierfranceschi M, Pan A. Switch from oral anticoagulants to parenteral heparin in SARS-CoV-2 hospitalized patients [published online ahead of print, 2020 Apr 15]. Intern Emerg Med 2020;1-3. doi: 10.1007/s11739-020-02331-1 Go to original source... Go to PubMed...
    14. Tulino D, Imbalzano E, Casale M, et al. Treatment failure of low molecular weight heparin in diabetic patient. Int J Cardiol 2013;168:e63-e64. Go to original source... Go to PubMed...
    15. Dattilo G, Lamari A, Di Bella G, et al. Treatment failure of low molecular weight heparin bridging therapy. Int J Cardiol 2013;167:e106-e107. Go to original source... Go to PubMed...

    This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (CC BY-NC 4.0), which permits non-comercial use, distribution, and reproduction in any medium, provided the original publication is properly cited. No use, distribution or reproduction is permitted which does not comply with these terms.


    Return to the content


    Cor et Vasa

    You are accessing a site intended for medical professionals, not the lay public. The site may also contain information that is intended only for persons authorized to prescribe and dispense medicinal products for human use.

    I therefore confirm that I am a healthcare professional under Act 40/1995 Coll. as amended by later regulations and that I have read the definition of a healthcare professional.


    No
    Yes